Company
ASX:RAC
Racura Oncology (ASX: RAC) is a Phase 3 stage clinical biopharmaceutical company with a mission to silence cancer. Racura’s lead asset, (E,E)-bisantrene, is a small molecule anticancer agent that primarily functions via G4-DNA & RNA binding, leading to potent silencing of the important cancer growth regulator MYC. (E,E)-bisantrene has demonstrated therapeutic activity in cancer patients with a well characterised safety profile. Recent discoveries made by Racura have enabled composition of matter IP filings that provide for 20 years of patent protection over (E,E)-bisantrene. Racura Oncology is advancing a proprietary formulation of (E,E)-bisantrene (RC220) to address the high unmet needs of patients across multiple oncology indications, with a Phase 3 clinical program in acute myeloid leukaemia (AML), a Phase 1a/b program in mutant epidermal growth factor receptor non-small cell lung cancer (EGFRm NSCLC), and a Phase 1a/b program in combination with the anthracycline doxorubicin, where we aim to deliver both cardioprotection and enhanced anticancer activity for solid tumour patients. Racura has collaborated with Astex, Emory University, Purdue University, MD Anderson, Sheba City of Health, UNC School of Medicine, University of Wollongong, and University of Newcastle. Racura is actively exploring partnerships, licence agreements, or a commercial merger and acquisition to accelerate access to RC220 for patients with cancer across the world.
130 stories · page 6 of 7
“The synergy that has now been observed with a diverse range of kinase inhibitors suggests possibilities for the clinical use of Zantrene in combination with kinase inhibitors far beyond melanoma," chief scientific officer Dr Daniel Tillett
Race could begin a human Zantrene trial with melanoma patients as early as 2023, depending on the outcomes of additional preclinical work.
Race believes the research, which explores Zantrene’s utility in the pancreatic and colorectal cancer spaces, complements its own findings that Zantrene can inhibit FTO in AML, melanoma and clear cell renal cell carcinoma.
“We are pleased that we have received strong interest in our BISECT (RAC-006) EMD AML and MDS study from experienced European haematologists. These clinicians identify a significant unmet need for the treatment of EMD AML and MDS and want t
“The positive results from the first stage of this trial in such a heavily pre-treated relapsed or refractory acute myeloid leukaemia population is encouraging, especially with three of the patients being subsequently bridged to transplant,
“Guy [Breitenbucher] will provide Race with a level of drug development knowledge and experience rarely found in Australia and his appointment is a significant enabler for our company and its development plans," says CEO Phillip Lynch.
The open-label Phase 1 trial will recruit up to 60 patients with confirmed extramedullary acute myeloid leukaemia (AML) at up to 10 clinical sites in Australia and Europe.
In breakthrough preclinical research, the company discovered that Zantrene protects from anthracycline-induced heart damage, while in tandem acting with anthracyclines and proteasome inhibitors to improve their ability to target breast canc
“We are pleased to enter into this important collaboration with Astex and wish to thank them for their interest and support of this clinical trial targeting FTO using the novel combination of ASTX727 and low dose bisantrene in AML and high-
“The optimised drug combination and schedule identified in this preclinical mouse study will be rapidly translated to the clinic via our extramedullary AML trial,” chief scientific officer Dr Daniel Tillett said.
Race is pursuing a three-pillar strategy to enhance partnering, licensing or sale opportunities to a scaled pharmaceutical company via advancing Zantrene in pre-clinical and clinical trials across a number of cancer targets.
“Advanced kidney cancer has a large unmet need for improved treatment options and Zantrene in combination with existing treatments may offer new hope for patients with this devastating disease," says chief scientific officer Dr Daniel Tille
“This work provides further preclinical data to support our upcoming Phase 1b/2 extramedullary AML trial in Australian and Europe, where patients will be treated with Zantrene in combination with decitabine or cytarabine,” CHM chief scienti
Christina Manfre, a partner at PKF Sydney, will provide leadership to Race Oncology’s financial analysis, reporting and strategic financial needs.
“The increased refund for FY21 is representative of the enhanced investment we made into R&D as we expanded our Zantrene clinical and supporting programs," says MD.
A consortium of crypto investors has offered to buy Bradford FC, while well-known bitcoin investor Peter McCormack has purchased a lower league football club Bedford FC.
“The number of applications reflects enthusiasm for the significant potential of our lead drug Zantrene and this enables us to implement our planned clinical and drug development plans across the three-pillar program,” managing director and
This strategically important collaboration will underpin a cardio-protective Phase 2b clinical trial in cancer patients at high risk of anthracycline-induced heart damage, which is expected to begin treating patients in late 2022.
“Zantrene is the first anti-cancer agent that we have found to exhibit a cardioprotective profile while being synergistically effective as an anti-cancer treatment," says University of Newcastle associate professor Doan Ngo.
The funding will be used to advance clinical projects for Race’s cancer drug Bisantrene.
